Zentalis Pharmaceuticals, Inc. Stock Price, News & Analysis

Zentalis Pharmaceuticals (Nasdaq: ZNTL) said management will participate in two investor events in November 2025: a Guggenheim Healthcare Innovation fireside on Nov 11, 2025 at 3:30 p.m. ET and a Stifel Healthcare presentation on Nov 12, 2025 at 8:00 a.m. ET.

Live webcasts and archived recordings will be available under the Events & Presentations tab on the company Investor & Media website. The company is a clinical-stage biopharma developing a WEE1 inhibitor for ovarian cancer and other tumors.

Zentalis (Nasdaq: ZNTL) announced four azenosertib poster presentations at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22–26, 2025 in Boston.

Presentations include Phase 1 dose escalation/expansion results, Cyclin E1 biomarker findings supporting late‑stage development in Cyclin E1‑positive platinum‑resistant ovarian cancer (noted as ~50% of PROC), a trial‑in‑progress DENALI Part 2 biomarker study (GOG‑3066), and a trastuzumab deruxtecan + azenosertib combination study in HER2‑expressing tumors. Posters are scheduled October 23–24, 2025 and will be available via Zentalis' Publications page on the presentation days.

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing WEE1 inhibitors for ovarian cancer treatment, has announced equity inducement grants. The company granted non-qualified stock options to newly hired employees, including 400,000 shares to James B. Bucher, the new Chief Legal Officer, and 15,000 shares to two additional employees.

The options, granted under the 2022 Inducement Plan, have an exercise price of $1.54 per share and a 10-year term. They will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over three years, subject to continued employment.

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a WEE1 inhibitor for ovarian cancer treatment, has announced inducement grants under its 2022 Employment Inducement Incentive Award Plan. The company granted stock options for 381,000 shares to six new employees.

The options, priced at $1.72 per share, will vest over four years with 25% vesting in the first year and the remaining 75% vesting monthly over three years. These grants, approved by the Compensation Committee, comply with Nasdaq Listing Rule 5635(c)(4) and are designed to attract new talent to the company.

Zentalis Pharmaceuticals (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company, will participate in three major investor conferences in September 2025. The company, which is developing a potentially first-in-class WEE1 inhibitor for ovarian cancer and other tumor types, will present at:

• Wells Fargo Healthcare Conference (Boston) - September 4, 10:15 AM ET
• H.C. Wainwright Global Investment Conference (New York) - September 8, 2:30 PM ET
• Morgan Stanley Global Healthcare Conference (New York) - September 9, 7:00 AM ET

Live webcasts and recordings will be available on the company's website under the "Events & Presentations" section.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) has appointed James B. Bucher, JD as Chief Legal Officer and Corporate Secretary, effective September 18, 2025. Bucher brings over 30 years of life sciences legal experience, most recently serving as Chief Legal Officer at Harpoon Therapeutics where he led the company's acquisition by Merck in 2024.

He succeeds Andrea Paul, who served since 2022 and is departing to join an international law firm. Bucher's extensive experience includes corporate strategy, governance, capital raising, and M&A, having overseen more than $1 billion in capital raising at Exelixis and playing a key role in Alder Biopharmaceuticals' $2.4 billion acquisition by Lundbeck.

The appointment comes as Zentalis advances registration-intent clinical trials for azenosertib, their potentially first-in-class and best-in-class WEE1 inhibitor for ovarian cancer treatment.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported Q2 2025 financial results and provided updates on its clinical progress. The company's lead candidate azenosertib is advancing in the Phase 2 DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer (PROC), with topline data expected by year-end 2026.

The company maintains a strong financial position with $303.4 million in cash and equivalents, providing runway into late 2027. Operating expenses decreased to $36.1 million from $65.1 million year-over-year, reflecting the company's strategic restructuring announced in January 2025. R&D expenses decreased to $27.6 million from $48.4 million in the prior year.

Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing a WEE1 inhibitor for ovarian cancer and other tumor types, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4).

The company's Compensation Committee granted stock options to purchase 14,000 shares to one newly hired employee under the 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $1.19 per share, matching the closing price on the grant date. The options feature a 10-year term with four-year vesting, including 25% vesting after the first year and the remaining 75% vesting monthly over three years, contingent on continued employment.

Zentalis Pharmaceuticals announced the granting of inducement stock options to four newly hired employees on June 2, 2025. The Compensation Committee approved non-qualified stock options to purchase 137,400 shares of common stock under the company's 2022 Employment Inducement Incentive Award Plan. The options have an exercise price of $1.28 per share, matching the closing price on Nasdaq that day. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over three years, contingent on continued employment. Zentalis, a clinical-stage biopharmaceutical company, is developing a potential first-in-class WEE1 inhibitor for ovarian cancer and other tumor types.